Tyra Biosciences, Inc. TYRA
Nov 11, 2026, 12:57 PM EST
- YTD
- -20.01%
- 1 year
- +38.99%
- Market cap
- 1.45B
- EPS (ttm)
- -2.63
- Shares out
- 68.76M
- Forward P/E
- -7.58
- YTD return
- -20.01%
- 1-year return
- +38.99%
- Volume
- 191.44K
- Avg volume
- 836.02K
- Open
- 20.98
- Previous close
- 21.00
- Day's range
- 20.72 – 21.37
- 52-week range
- 14.67 – 40.65
- Beta
- 0.67
- Price target
- 47.45 (+125.7%)
- Earnings date
- Mar 24, 2027
5D -0.57 (-2.65%)
Key statistics
- Enterprise value
- 982.43M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -63.07M
- Total cash
- 353.94M
- Total debt
- 5.58M
- Return on equity
- -45.31%
- Short % of float
- 22.90%
- 50-day average
- 22.12
- 200-day average
- 29.63
Analyst view
- Target (low)
- 29.00
- Target (mean)
- 47.45
- Target (high)
- 59.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 24, 2027
Expected Mar 24, 2027. Consensus EPS estimate -0.665.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 24, 2027 | Mar 30, 2027 | -0.70067 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.66867 | -0.74 | -0.07 | -10.67% |
| Aug 4, 2026 | Jun 30, 2026 | -0.64989 | -0.69 | -0.04 | -6.17% |
| May 13, 2026 | Mar 31, 2026 | -0.60 | -0.64 | -0.04 | -6.67% |
| Mar 2, 2026 | Dec 31, 2025 | -0.54 | -0.57 | -0.03 | -5.56% |
| Nov 5, 2025 | Sep 30, 2025 | -0.50 | -0.50 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Sep 22, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 10, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 4, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 17, 2026 | Jones Trading | init | — | Buy |
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tyra.bio
News
Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday 
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57 
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $27 
Tyra Biosciences Q3 EPS $(0.74) Misses $(0.69) Estimate 
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights 
Tyra Biosciences to Participate in Upcoming Investor Conferences 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40 - HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
Stock Market Today: S&P 500, Dow and Nasdaq Futures Fall as Brent Hovers Near $107 and FOMC Commences Two-Day Meeting— MSTR, CRWD, BMM in Focus (UPDATED)
Your note
Sign in to keep a note on TYRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHAR BHAVESH | Chief Operating Officer | Stock Award(Grant) | May 4, 2026 | 15,013 |
| BENSEN DANIEL | Officer | Sale | Feb 11, 2026 | 146,981 |
| FUHRMAN ALAN CPA | Chief Financial Officer | Stock Award(Grant) | May 4, 2026 | 36,164 |
| HARRIS TODD JAMES | Chief Executive Officer | Stock Award(Grant) | May 4, 2026 | 1,437,630 |
| KAPLAN GILLA | Director | Conversion of Exercise of derivative security | Mar 25, 2026 | 28,231 |
| KJELLSON NINA S | Director | Sale | Feb 4, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 20.44% | 12,198,625 | 256.17M | Jun 29, 2026 |
| FMR, LLC | 14.95% | 8,920,513 | 187.33M | Jun 29, 2026 |
| Jupiter Topco LLC | 7.29% | 4,352,448 | 91.40M | Jun 29, 2026 |
| Alta Partners Management Company, L.P. | 6.41% | 3,823,425 | 80.29M | Jun 29, 2026 |
| Nextech Invest, Ltd. | 5.95% | 3,553,585 | 74.63M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.44% | 3,248,980 | 68.23M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Securities Fund-Fidelity OTC Portfolio | 5.56% | 3,317,036 | 69.66M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.94% | 1,154,855 | 24.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.90% | 1,135,472 | 23.84M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.60% | 956,773 | 20.09M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.33% | 793,140 | 16.66M | Jun 29, 2026 |
| Fidelity Advisor Series I-Fidelity Advisor Equity Growth Fund | 1.14% | 678,600 | 14.25M | Sep 29, 2026 |